Why carry out this study?

Pelvic congestion syndrome (PCS) as a result of pelvic varicose veins represents a form of chronic venous disease (CVD). However, while there is substantial evidence for the role of venoactive drugs in the management of CVD, data on their use in patients with PCS are limited.

This placebo-controlled study assessed the clinical efficacy of the venoactive agent micronized purified flavonoid fraction (MPFF) in female patients with PCS.

What was learned from the study?

Conservative treatment with MPFF was associated with improved quality of life and reduced symptom severity compared with control.

These results provide supporting data for the use of MPFF as a safe and effective treatment for PCS in routine clinical practice.